EMA committee recommends approval for injectable version of Merck's Keytruda

The European Medicines Agency's committee has recommended approval for a subcutaneous formulation of Merck's blockbuster cancer therapy Keytruda, offering significantly faster administration and enhanced patient access, which is crucial for the drug's continued growth. This development, coupled with an anticipated U.S. FDA decision by September 23 and a new indication recommendation for advanced head and neck cancer, strengthens Keytruda's market position, with final EU marketing authorization expected in Q4 2025.

Analysis

Merck has received a significant positive regulatory signal from the European Medicines Agency's committee, which recommended approval for a subcutaneous formulation of its blockbuster cancer therapy, Keytruda. This new formulation is a critical life-cycle management tool, as it dramatically reduces administration time to as little as one minute, compared to the traditional intravenous method, thereby enhancing patient convenience and expanding potential treatment settings. This development is pivotal for Merck, which relies on Keytruda to fuel its growth. The positive recommendation is further bolstered by a pending U.S. FDA decision on the same formulation, with an action date set for September 23, representing a major near-term catalyst. While a final European Commission marketing authorization is not expected until the fourth quarter of 2025, this initial endorsement de-risks the European approval pathway. Additionally, the committee's concurrent recommendation to approve Keytruda for a new indication in advanced head and neck cancer further expands the drug's addressable market and revenue potential.

Key Decisions for Investors

• Investors should closely monitor the upcoming U.S. FDA decision by September 23, as an approval would act as a significant near-term catalyst by opening the lucrative U.S. market to the more convenient formulation.
• This positive regulatory development strengthens the long-term durability of the Keytruda franchise, potentially mitigating future revenue erosion from competition and justifying a more bullish outlook on Merck's core earnings driver.
• Consider the strategic advantage this new formulation provides in the competitive immunotherapy landscape, as enhanced patient convenience could solidify Keytruda's market share against rival treatments.